PMC6041387_01
(A) Patient 1 exhibited a complete response after three cycles of treatment with pembrolizumab plus cytokine-induced killer (CIK) cell transfer and continues to be in remission 537 days posttreatment (as of 12/02/2017). (B) Patient 2 exhibited a partial response after two cycles of treatment with pembrolizumab plus CIK cell transfer and continues to be in remission on day 185 after treatment (as of 12/02/2017).
fimmu-09-01513-g001.jpg
PMC6041387_02_fimmu-09-01513-g001.jpg
F1
Follow-up imaging showed a near-complete response after treatment with eight cycles of pembrolizumab in combination with seven cycles of CIK cell transfer (Table S1 in Supplementary Material), and the patient continues to be in remission 185 days posttreatment (Figure 1B).
PMC6041387_02
(A) Patient 1 exhibited a complete response after three cycles of treatment with pembrolizumab plus cytokine-induced killer (CIK) cell transfer and continues to be in remission 537 days posttreatment (as of 12/02/2017). (B) Patient 2 exhibited a partial response after two cycles of treatment with pembrolizumab plus CIK cell transfer and continues to be in remission on day 185 after treatment (as of 12/02/2017).
fimmu-09-01513-g001.jpg
PMC6041387_02_fimmu-09-01513-g001.jpg
F1
Follow-up imaging showed a near-complete response after treatment with eight cycles of pembrolizumab in combination with seven cycles of CIK cell transfer (Table S1 in Supplementary Material), and the patient continues to be in remission 185 days posttreatment (Figure 1B).
(A) Immunohistochemical analysis in Patient 1 shows no membranous expression of programmed cell death-1 or PD-L1 in the tumor cells and the small background cells surrounding the malignant tumor cells. CD3+ cells are observed among the tumor cells. (B) Immunohistochemical analysis of a pretreatment tumor in Patient 2 shows focal membranous expression of PD-L1 in the tumor cells, with additional expression seen on the small background cells surrounding the malignant tumor cells. Abundant CD3+ cells are identified among the tumor cells (magnification: left panel, 10x; right panel, 40x).
fimmu-09-01513-g002.jpg
PMC6041387_02_fimmu-09-01513-g002.jpg
F2
T cell infiltration, but no PD-1 or PD-L1 expression (Figure 2A). The tumor cells from Patient 2 strongly expressed PD-L1, and there was extensive tumor infiltration by CD3+ T cells; however, no PD-1 staining was seen (Figure 2B).
Whole exome sequencing analysis revealed a low tumor mutation burden, lack of mutation in MMR or driver genes, and presence of non-synonymous single nucleotide variants or fs-indels.
fimmu-09-01513-g003.jpg
PMC6041387_02_fimmu-09-01513-g003.jpg
F3
The TMB in patient 2 was higher than that in patient 1 (2.4 versus 0.8/Mb, respectively); however, no mutations in MMR-associated genes occurred in either patient (Figure 3).